Literature DB >> 10584879

Expression and subcellular localization of cyclin D1 protein in epithelial ovarian tumour cells.

K K Dhar1, K Branigan, J Parkes, R E Howells, P Hand, C Musgrove, R C Strange, A A Fryer, C W Redman, P R Hoban.   

Abstract

The expression of cyclin D1 protein in tumour sections from 81 patients with epithelial ovarian cancer was analysed using immunohistochemistry. The tumours that overexpressed cyclin D1 in more than 10% of neoplastic cells were considered positive. Thus overexpression of cyclin D1 was observed in 72/81 (89%) of the cases examined. Protein was detected in both the nucleus and the cytoplasm in 24/81 (30%) and localized exclusively in the cytoplasm in 48/81 (59%) of the tumours. Cyclin D1 was overexpressed in both borderline and invasive tumours. There was no association between protein overexpression and tumour stage and differentiation. Furthermore, no correlation between cyclin D1 expression and clinical outcome was observed. However, in tumours overexpressing cyclin D1 (n = 72), the proportion displaying exclusively cytoplasmic localization of protein was higher in those with serous compared with non-serous histology (P = 0.004, odds ratio 4.8, 95% confidence interval 1.4-19.1). Western analysis using a monoclonal antibody to cyclin D1 identified a 36 kDa protein in homogenates from seven tumours displaying cytoplasmic only and one tumour demonstrating both nuclear and cytoplasmic immunostaining. Using restriction fragment length polymorphism polymerase chain reaction and PCR-multiplex analysis, amplification of the cyclin D1 gene (CCND1 was detected in 1/29 of the tumours demonstrating overexpression of cyclin D1 protein. We conclude that deregulation of CCND1 expression leading to both cytoplasmic and nuclear protein localization is a frequent event in ovarian cancer and occurs mainly in the absence of gene amplification.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10584879      PMCID: PMC2374327          DOI: 10.1038/sj.bjc.6690826

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  36 in total

1.  Alternatively spliced forms of cyclin D1 modulate entry into the cell cycle in an inverse manner.

Authors:  H Sawa; T A Ohshima; H Ukita; H Murakami; Y Chiba; H Kamada; M Hara; I Saito
Journal:  Oncogene       Date:  1998-04-02       Impact factor: 9.867

2.  A dominant-negative cyclin D1 mutant prevents nuclear import of cyclin-dependent kinase 4 (CDK4) and its phosphorylation by CDK-activating kinase.

Authors:  J A Diehl; C J Sherr
Journal:  Mol Cell Biol       Date:  1997-12       Impact factor: 4.272

3.  Non-surgical aspects of ovarian cancer.

Authors: 
Journal:  Lancet       Date:  1994-02-05       Impact factor: 79.321

4.  Association of glutathione S-transferase GSTM1 and GSTT1 null genotypes with clinical outcome in epithelial ovarian cancer.

Authors:  R E Howells; C W Redman; K K Dhar; P Sarhanis; C Musgrove; P W Jones; J Alldersea; A A Fryer; P R Hoban; R C Strange
Journal:  Clin Cancer Res       Date:  1998-10       Impact factor: 12.531

5.  Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma.

Authors:  N Nishida; Y Fukuda; T Komeda; R Kita; T Sando; M Furukawa; M Amenomori; I Shibagaki; K Nakao; M Ikenaga
Journal:  Cancer Res       Date:  1994-06-15       Impact factor: 12.701

6.  Multiple breakpoints within the BCL-1 locus in B-cell lymphoma: rearrangements of the cyclin D1 gene.

Authors:  C J de Boer; S Loyson; P M Kluin; H C Kluin-Nelemans; E Schuuring; J H van Krieken
Journal:  Cancer Res       Date:  1993-09-15       Impact factor: 12.701

7.  A novel cyclin encoded by a bcl1-linked candidate oncogene.

Authors:  T Motokura; T Bloom; H G Kim; H Jüppner; J V Ruderman; H M Kronenberg; A Arnold
Journal:  Nature       Date:  1991-04-11       Impact factor: 49.962

8.  Cyclin D1 expression in squamous cell carcinomas of the head and neck and in oral mucosa in relation to proliferation and apoptosis.

Authors:  V M Kotelnikov; J S Coon; S Mundle; S Kelanic; S LaFollette; I V Taylor S; J Hutchinson; W Panje; D D Caldarelli; H D Preisler
Journal:  Clin Cancer Res       Date:  1997-01       Impact factor: 12.531

9.  Cyclin D1 gene amplification in human laryngeal squamous cell carcinomas: prognostic significance and clinical implications.

Authors:  A Bellacosa; G Almadori; S Cavallo; G Cadoni; J Galli; G Ferrandina; G Scambia; G Neri
Journal:  Clin Cancer Res       Date:  1996-01       Impact factor: 12.531

10.  Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining.

Authors:  C Gillett; V Fantl; R Smith; C Fisher; J Bartek; C Dickson; D Barnes; G Peters
Journal:  Cancer Res       Date:  1994-04-01       Impact factor: 12.701

View more
  16 in total

Review 1.  Cyclin D as a therapeutic target in cancer.

Authors:  Elizabeth A Musgrove; C Elizabeth Caldon; Jane Barraclough; Andrew Stone; Robert L Sutherland
Journal:  Nat Rev Cancer       Date:  2011-07-07       Impact factor: 60.716

2.  CDK4 protein is degraded by anaphase-promoting complex/cyclosome in mitosis and reaccumulates in early G1 phase to initiate a new cell cycle in HeLa cells.

Authors:  Huabo Chen; Xiaowei Xu; Guopeng Wang; Boyan Zhang; Gang Wang; Guangwei Xin; Junjun Liu; Qing Jiang; Hongyin Zhang; Chuanmao Zhang
Journal:  J Biol Chem       Date:  2017-04-26       Impact factor: 5.157

Review 3.  Microenvironment and pathogenesis of epithelial ovarian cancer.

Authors:  Antonio F Saad; Wei Hu; Anil K Sood
Journal:  Horm Cancer       Date:  2010-12       Impact factor: 3.869

4.  Cyclin D1 polymorphism and expression in patients with squamous cell carcinoma of the head and neck.

Authors:  S L Holley; G Parkes; C Matthias; U Bockmühl; V Jahnke; K Leder; R C Strange; A A Fryer; P R Hoban
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

5.  Cyclin D1 predicts the prognosis of advanced serous ovarian cancer.

Authors:  Tomoko Hashimoto; Nozomu Yanaihara; Aikou Okamoto; Takashi Nikaido; Misato Saito; Satoshi Takakura; Makoto Yasuda; Hiroshi Sasaki; Kazunori Ochiai; Tadao Tanaka
Journal:  Exp Ther Med       Date:  2011-01-18       Impact factor: 2.447

6.  The DNA deaminase APOBEC3B interacts with the cell-cycle protein CDK4 and disrupts CDK4-mediated nuclear import of Cyclin D1.

Authors:  Jennifer L McCann; Madeline M Klein; Evelyn M Leland; Emily K Law; William L Brown; Daniel J Salamango; Reuben S Harris
Journal:  J Biol Chem       Date:  2019-06-19       Impact factor: 5.157

7.  Expression of cyclin d1 and its association with disease characteristics in bladder cancer.

Authors:  Pradeep Kumar Kopparapu; Stephen A Boorjian; Brian D Robinson; Martin Downes; Lorraine J Gudas; Nigel P Mongan; Jenny L Persson
Journal:  Anticancer Res       Date:  2013-12       Impact factor: 2.480

8.  Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma.

Authors:  Peter Schraml; Georg Schwerdtfeger; Felix Burkhalter; Anna Raggi; Dietmar Schmidt; Teresa Ruffalo; Walter King; Kim Wilber; Michael J Mihatsch; Holger Moch
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

9.  CyclinD1 promotes lymph node metastasis by inducing lymphangiogenesis in human ovarian carcinoma.

Authors:  Minhua Li; Weiping Zheng; Cheng Wang
Journal:  Int J Clin Exp Pathol       Date:  2018-07-01

10.  Distinct expression pattern and post-transcriptional regulation of cell cycle genes in the glandular epithelia of avian ovarian carcinomas.

Authors:  Jin-Young Lee; Wooyoung Jeong; Ji-Hye Kim; Jinyoung Kim; Fuller W Bazer; Jae Yong Han; Gwonhwa Song
Journal:  PLoS One       Date:  2012-12-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.